Better support for taking medicines for people with drug-resistant TB and HIV in South Africa
Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa
['FUNDING_R01'] · COLUMBIA UNIVERSITY HEALTH SCIENCES · NIH-11472086
This project tries combining mobile phone reminders and counseling to help people in South Africa with drug-resistant tuberculosis and HIV stick to their new medicines.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | COLUMBIA UNIVERSITY HEALTH SCIENCES (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11472086 on ClinicalTrials.gov |
What this research studies
You would be offered phone-based reminders and psychosocial counseling together with the new oral TB drug bedaquiline and a dolutegravir-based HIV regimen. The project uses an adaptive approach, changing the type or intensity of support based on how well people are taking their medicines. Participation takes place through clinics in South Africa and includes regular check-ins, adherence monitoring, and health outcome tracking. The aim is to find the best mix of mobile and in-person support to help people finish treatment and prevent drug resistance.
Who could benefit from this research
Good fit: People living in South Africa who have drug-resistant tuberculosis and HIV and are starting (or recently started) bedaquiline-containing TB treatment and dolutegravir-based antiretroviral therapy.
Not a fit: People without drug-resistant TB and HIV, those not on the specified drug regimens, or individuals who cannot access a mobile phone or participating clinics may not benefit from this project.
Why it matters
Potential benefit: If successful, this could improve medicine-taking, reduce deaths and treatment failure, and lower the chance of new drug resistance for people with DR-TB and HIV.
How similar studies have performed: Phone reminders and counseling have shown mixed but sometimes positive effects on HIV or TB adherence separately, while combining tailored mHealth and psychosocial support for DR-TB/HIV on these new regimens is relatively new.
Where this research is happening
NEW YORK, UNITED STATES
- COLUMBIA UNIVERSITY HEALTH SCIENCES — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: O'DONNELL, MAX — COLUMBIA UNIVERSITY HEALTH SCIENCES
- Study coordinator: O'DONNELL, MAX
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus